Genascence

Genascence is a clinical-stage biotechnology company focused on gene therapy to address prevalent musculoskeletal diseases, particularly osteoarthritis. This condition is the leading cause of disability and chronic pain, posing significant health risks, including opioid addiction. Genascence's innovative approach aims to improve the treatment of osteoarthritis by alleviating symptoms and slowing disease progression, ultimately enhancing patient care and recovery outcomes. The company's research and development efforts are directed toward providing effective solutions for both common and rare disorders associated with musculoskeletal health.